FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:AGPAT2-CDC42SE1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: AGPAT2-CDC42SE1
FusionPDB ID: 2927
FusionGDB2.0 ID: 2927
HgeneTgene
Gene symbol

AGPAT2

CDC42SE1

Gene ID

10555

56882

Gene name1-acylglycerol-3-phosphate O-acyltransferase 2CDC42 small effector 1
Synonyms1-AGPAT2|BSCL|BSCL1|LPAAB|LPAAT-betaSCIP1|SPEC1
Cytomap

9q34.3

1q21.3

Type of geneprotein-codingprotein-coding
Description1-acyl-sn-glycerol-3-phosphate acyltransferase beta1-AGP acyltransferase 21-AGPAT 21-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase, beta)lysophosphatidic acid acyltransferase-betatesticular tissue protein Li 143CDC42 small effector protein 11300002M12RikCDC42-binding protein SCIP1signaling molecule SPEC1 betasmall effector of CDC42 protein 1small protein effector 1 of Cdc42
Modification date2020031320200313
UniProtAcc

O15120

Main function of 5'-partner protein: FUNCTION: Converts 1-acyl-sn-glycerol-3-phosphate (lysophosphatidic acid or LPA) into 1,2-diacyl-sn-glycerol-3-phosphate (phosphatidic acid or PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone. {ECO:0000269|PubMed:15629135, ECO:0000269|PubMed:19075029, ECO:0000269|PubMed:21873652, ECO:0000269|PubMed:9242711}.

Q9NRR8

Main function of 5'-partner protein: FUNCTION: Probably involved in the organization of the actin cytoskeleton by acting downstream of CDC42, inducing actin filament assembly. Alters CDC42-induced cell shape changes. In activated T-cells, may play a role in CDC42-mediated F-actin accumulation at the immunological synapse. May play a role in early contractile events in phagocytosis in macrophages. {ECO:0000269|PubMed:10816584, ECO:0000269|PubMed:15840583, ECO:0000269|PubMed:17045588}.
Ensembl transtripts involved in fusion geneENST idsENST00000371694, ENST00000371696, 
ENST00000538402, 
ENST00000492796, 
ENST00000357235, ENST00000439374, 
ENST00000540998, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score1 X 1 X 1=17 X 8 X 5=280
# samples 19
** MAII scorelog2(1/1*10)=3.32192809488736log2(9/280*10)=-1.63742992061529
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: AGPAT2 [Title/Abstract] AND CDC42SE1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: AGPAT2 [Title/Abstract] AND CDC42SE1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)AGPAT2(139571413)-CDC42SE1(151027602), # samples:3
Anticipated loss of major functional domain due to fusion event.AGPAT2-CDC42SE1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
AGPAT2-CDC42SE1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
AGPAT2-CDC42SE1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
AGPAT2-CDC42SE1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
AGPAT2-CDC42SE1 seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
AGPAT2-CDC42SE1 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr9:139571413/chr1:151027602)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across AGPAT2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across CDC42SE1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000371694AGPAT2chr9139571413-ENST00000439374CDC42SE1chr1151027602-309253341718225
ENST00000371694AGPAT2chr9139571413-ENST00000540998CDC42SE1chr1151027602-309053341718225
ENST00000371694AGPAT2chr9139571413-ENST00000357235CDC42SE1chr1151027602-309053341718225
ENST00000371696AGPAT2chr9139571413-ENST00000439374CDC42SE1chr1151027602-311755866743225
ENST00000371696AGPAT2chr9139571413-ENST00000540998CDC42SE1chr1151027602-311555866743225
ENST00000371696AGPAT2chr9139571413-ENST00000357235CDC42SE1chr1151027602-311555866743225

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000371694ENST00000439374AGPAT2chr9139571413-CDC42SE1chr1151027602-0.0024861960.9975138
ENST00000371694ENST00000540998AGPAT2chr9139571413-CDC42SE1chr1151027602-0.0026002750.9973997
ENST00000371694ENST00000357235AGPAT2chr9139571413-CDC42SE1chr1151027602-0.0026002750.9973997
ENST00000371696ENST00000439374AGPAT2chr9139571413-CDC42SE1chr1151027602-0.0026020690.9973979
ENST00000371696ENST00000540998AGPAT2chr9139571413-CDC42SE1chr1151027602-0.0027147460.99728525
ENST00000371696ENST00000357235AGPAT2chr9139571413-CDC42SE1chr1151027602-0.0027147460.99728525

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for AGPAT2-CDC42SE1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
AGPAT2chr9139571413CDC42SE1chr1151027602533164VMADLGERMVRENKKKRRRIDRTMIG
AGPAT2chr9139571413CDC42SE1chr1151027602558164VMADLGERMVRENKKKRRRIDRTMIG

Top

Potential FusionNeoAntigen Information of AGPAT2-CDC42SE1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Potential FusionNeoAntigen Information of AGPAT2-CDC42SE1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
AGPAT2-CDC42SE1_139571413_151027602.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1102GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1102LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1102ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1114GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1114ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1114LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1116GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1116LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1116ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1120GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1120ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1120LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1121GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1121LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1121ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1136GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1136LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1136ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1148GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1148LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1159GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1165GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1165LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1165ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1168GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1168ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1168LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1170GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1170LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1170ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1186GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1186ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1186LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1301GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1301LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1301ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1302GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1302ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1302LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1308GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1308LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1315GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1315ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1315LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1316GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1316ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1316LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1317GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1319GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1319ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1319LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1320GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1320LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1320ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1322GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1322LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1322ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1323GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1323ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1323LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1327GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1327LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1327ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1329GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1329ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1329LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1334GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1334ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1334LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1335GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1335LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1335ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1339GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1339ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1339LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1341GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1341LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1341ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1351GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1351LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1351ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1352GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1352LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1352ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1353GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1353ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1353LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1357GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1357ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1357LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1359GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1359LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1359ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1361GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1361ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1361LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1361DLGERMVRENKKKRR318
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1361RMVRENKKKRRRIDR722
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1364GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1364LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1364ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1368GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1368LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1368ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1369GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1369LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1369ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1370GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1370LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1371GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1371LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1371ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1371DLGERMVRENKKKRR318
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1372GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1372LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1373GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1373ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1373LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1374GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1374ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1374LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1378GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1378LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1378ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1379GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1379LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1379ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1380GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1380LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1380ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1383GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1383LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1383ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1384GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1384LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1387GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1387LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1387ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1391GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1391LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1391ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1392GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1392LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1392ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1396GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1396ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1396LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1397GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1397ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1397LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1398GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1398LGERMVRENKKKRRR419
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1398ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1399GERMVRENKKKRRRI520
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1399ERMVRENKKKRRRID621
AGPAT2-CDC42SE1chr9139571413chr1151027602533DRB1-1399LGERMVRENKKKRRR419

Top

Fusion breakpoint peptide structures of AGPAT2-CDC42SE1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of AGPAT2-CDC42SE1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score

Top

Vaccine Design for the FusionNeoAntigens of AGPAT2-CDC42SE1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
AGPAT2-CDC42SE1chr9139571413chr1151027602318DLGERMVRENKKKRRGACCTGGGCGAGCGCATGGTCAGGGAGAACAAGAAGAAGAGAAGA
AGPAT2-CDC42SE1chr9139571413chr1151027602419LGERMVRENKKKRRRCTGGGCGAGCGCATGGTCAGGGAGAACAAGAAGAAGAGAAGACGG
AGPAT2-CDC42SE1chr9139571413chr1151027602520GERMVRENKKKRRRIGGCGAGCGCATGGTCAGGGAGAACAAGAAGAAGAGAAGACGGATT
AGPAT2-CDC42SE1chr9139571413chr1151027602621ERMVRENKKKRRRIDGAGCGCATGGTCAGGGAGAACAAGAAGAAGAGAAGACGGATTGAC
AGPAT2-CDC42SE1chr9139571413chr1151027602722RMVRENKKKRRRIDRCGCATGGTCAGGGAGAACAAGAAGAAGAGAAGACGGATTGACCGG

Top

Information of the samples that have these potential fusion neoantigens of AGPAT2-CDC42SE1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample

Top

Potential target of CAR-T therapy development for AGPAT2-CDC42SE1

check button Predicted 3D structure. We used RoseTTAFold.
17_AGPAT2-CDC42SE1_3e9c0_pred.pdb


check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneAGPAT2chr9:139571413chr1:151027602ENST00000371694-35122_142164247.0TransmembraneHelical
HgeneAGPAT2chr9:139571413chr1:151027602ENST00000371694-3530_50164247.0TransmembraneHelical
HgeneAGPAT2chr9:139571413chr1:151027602ENST00000371696-36122_142164279.0TransmembraneHelical
HgeneAGPAT2chr9:139571413chr1:151027602ENST00000371696-3630_50164279.0TransmembraneHelical
HgeneAGPAT2chr9:139571413chr1:151027602ENST00000538402-37122_142164379.6666666666667TransmembraneHelical
HgeneAGPAT2chr9:139571413chr1:151027602ENST00000538402-3730_50164379.6666666666667TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result
AGPAT2chr9139571413ENST00000371694CDC42SE1chr1151027602ENST00000357235

Top

Related Drugs to AGPAT2-CDC42SE1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to AGPAT2-CDC42SE1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource